(S)-1-Dimethylamino-3-methyl-butan-2-ol | 112348-01-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (S)-1-Dimethylamino-3-methyl-butan-2-ol
• 英文别名: (2S)-1-(dimethylamino)-3-methylbutan-2-ol
• CAS: 112348-01-3
• 化学式: C₇H₁₇NO
• 分子量: 131.218
• InChiKey: CGVDIJPAUMTOMB-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-dimethylamino-3-methyl-2-oxobutane 在 Ru(OAc)2((S)-BINAP) 氢气 作用下， 以 甲醇 为溶剂， 反应 24.0h， 生成 (S)-1-Dimethylamino-3-methyl-butan-2-ol 、 (R)-1-Dimethylamino-3-methyl-butan-2-ol
  参考文献：
  名称：

  功能化酮的均相不对称氢化

  摘要：

  氢化 asymetrique en alcool de different cetones (aminocetones, cetols, cetoesters, cetoamides, cetothioester, cetoethers, dicetones, cetoacide) catalysee par des complexes du ruthenium(II) et du bis-diphenylphosphino-2,2'1'bina

  DOI：

  10.1021/ja00210a070

文献信息

• MONOCYCLIC COMPOUNDS AND THEIR USE AS TRPV1 LIGANDS
  申请人：Tafesse Laykea

  公开号：US20100120862A1

  公开（公告）日：2010-05-13

  The invention relates to compounds of formula I and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable derivative thereof.

  本发明涉及公式I的化合物及其药学上可接受的衍生物，包括含有公式I化合物或其药学上可接受的衍生物的有效量的组合物，以及治疗或预防疼痛、尿失禁、溃疡、炎症性肠病（IBD）和肠易激综合征（IBS）等疾病的方法，包括向需要的动物施用公式I化合物或其药学上可接受的衍生物的有效量。
• HETEROCYCLIC TRPV1 RECEPTOR LIGANDS
  申请人：Tafesse Laykea

  公开号：US20100137306A1

  公开（公告）日：2010-06-03

  The invention relates to compounds of formulae I(a)-I(d): and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formulae I(a)-I(d) or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of formulae I(a)-I(d) or a pharmaceutically acceptable derivative thereof.

  该发明涉及以下化合物的化学式：I(a)-I(d)，及其药学上可接受的衍生物，包括含有化合物I(a)-I(d)或其药学上可接受的衍生物的有效量的组合物，以及用于治疗或预防疼痛、尿失禁、溃疡、炎症性肠病和肠易激综合征等疾病的方法，包括向需要的动物施用化合物I(a)-I(d)或其药学上可接受的衍生物的有效量。
• BICYCLOHETEROARYL COMPOUNDS AND THEIR USE AS TRPV1 LIGANDS
  申请人：TAFESSE LAYKEA

  公开号：US20100130499A1

  公开（公告）日：2010-05-27

  The invention relates to compounds of formula I and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable derivative thereof.

  该发明涉及公式I的化合物及其药用可接受的衍生物，包含有效量的公式I化合物或其药用可接受的衍生物的组合物，以及治疗或预防疼痛、尿失禁、溃疡、炎症性肠病和肠易激综合征等疾病的方法，包括向需要治疗的动物施用公式I化合物或其药用可接受的衍生物的有效量。
• TRPV1 antagonists and uses thereof
  申请人：Purdue Pharma L.P.

  公开号：EP2604598A1

  公开（公告）日：2013-06-19

  The invention relates to compounds of formula I and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable derivative thereof.

  本发明涉及式 I 的化合物 及其药学上可接受的衍生物，包含有效量的式 I 化合物或其药学上可接受的衍生物的组合物，以及治疗或预防疼痛、UI、溃疡、IBD 和肠易激综合征等病症的方法，包括向有需要的动物施用有效量的式 I 化合物或其药学上可接受的衍生物。
• TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF
  申请人：Tafesse Laykea

  公开号：US20090170868A1

  公开（公告）日：2009-07-02

  The invention relates to compounds of formula IA and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formula IA or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of formula IA or a pharmaceutically acceptable derivative thereof.